The Antihypertensive Efficacy of the Combination of Irbesartan and Hydrochlorotfflazide Assessed by 24-Hour Ambulatory Blood Pressure Monitoring

Abstract

In a multicenter, double-blind, randomized trial, 178 patients with ambulatory diastolic blood pressure (BP) ⩾ 85 mm Hg and seated diastolic BP (SeDBP) 95–110 mm Hg received either once-daily irbesartan 75 mg/hydrochlorothiazide (HCTZ) 12.5 mg, irbesartan 150 mg/HCTZ 12.5 mg, or placebo for 8 weeks to assess reductions in 24-hour ambulatory BP and office BP. Safety and tolerability of all treatment regimens were also evaluated. BP results and therapeutic